Filing Flows › Halozyme Therapeutics (HALO) › Operating margin
Halozyme Therapeutics (HALO) operating margin by quarter
Halozyme Therapeutics' operating margin was 59.8% in Q3 2026 (third quarter 2026), +0.0 pts from Q2 2026. Over the last 6 quarters it ranged from 49.0% (Q1 2026) to 62.2% (Q2 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 59.8% | +0.0 pts | -1.7 pts |
| Q2 2026 | 59.8% | +10.8 pts | -2.3 pts |
| Q1 2026 | 49.0% | -12.5 pts | -4.5 pts |
| Q3 2025 | 61.5% | -0.6 pts | — |
| Q2 2025 | 62.2% | +8.7 pts | — |
| Q1 2025 | 53.4% | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' operating margin?
Halozyme Therapeutics' operating margin was 59.8% in Q3 2026 (third quarter 2026), +0.0 pts from Q2 2026.
How has Halozyme Therapeutics' operating margin changed?
Over the last 6 quarters it ranged from 49.0% (Q1 2026) to 62.2% (Q2 2025).